Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074347 | 0.82 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAMAPTALDH1A1CA2 | |
| SCHEMBL7271170 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAMAPTALDH1A1CA2 | |
| SCHEMBL7257961 | 0.80 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMAPTALDH1A1CA2 | |
| SCHEMBL24970550 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAMAPTALDH1A1CA2 | |
| SCHEMBL29087314 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAMAPTALDH1A1HTT | |
| SCHEMBL30596341 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAMAPTALDH1A1HTT | |
| SCHEMBL28195553 | 0.75 | HTT (0.75) | SMN1; SMN2LMNAMAPTALDH1A1HTT | |
| SCHEMBL27772412 | 0.74 | CA2 (0.53) | SMN1; SMN2LMNAMAPTALDH1A1CA2 | |
| SCHEMBL138372 | 0.74 | KDM4E (0.61) | LMNAMAPTALDH1A1CA2CA1 | |
| SCHEMBL141067 | 0.74 | CA2 (0.65) | SMN1; SMN2LMNAALDH1A1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | YAP1, ICOSLG, SPIN3 | SMN1; SMN2 1165/4885LMNA 4405/4885MAPT 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.